Author

Gerard Dijkstra

RELIABILITY AND RELATIVE CONSTRUCT VALIDITY OF A FOOD FREQUENCY QUESTIONNAIRE: THE GRONINGEN INFLAMMATORY BOWEL DISEASE NUTRITIONAL QUESTIONNAIRES (GINQ-FFQ)
RELIABILITY AND RELATIVE CONSTRUCT VALIDITY OF A FOOD FREQUENCY QUESTIONNAIRE: THE GRONINGEN INFLAMMATORY BOWEL DISEASE NUTRITIONAL QUESTIONNAIRES (GINQ-FFQ)

Gerard Dijkstra  et al.

PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?
PREHABILITATION STRATEGIES PRIOR TO ILEOCOLIC (RE-)RESECTION IN PATIENTS WITH CROHN’S DISEASE: A MISSED WINDOW OF OPPORTUNITY?

Gerard Dijkstra  et al.

THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY
THE INTERACTION OF GENETIC VARIANTS AND TOBACCO SMOKING IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A GENOME WIDE STUDY

Gerard Dijkstra  et al.

FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18
FAECALIBACTERIUM PRAUSNITZII MODULATES INTESTINAL MUCOSAL HEALTH VIA HIF1ALPHA-INDUCED EPITHELIAL PRODUCTION OF IL-18

Gerard Dijkstra  et al.

INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INVESTIGATION OF SOMATIC MUTATIONS IN BIOPSIES FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL
THE EFFECT OF RIBOFLAVIN SUPPLEMENTATION ON THE SYSTEMIC REDOX STATUS IN HEALTHY VOLUNTEERS: A POST-HOC ANALYSIS OF THE RIBOGUT TRIAL

Gerard Dijkstra  et al.

USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
USE OF TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS IS ASSOCIATED WITH ATTENUATED IGG ANTIBODY RESPONSE AGAINST SARS-COV-2 IN VACCINATED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE
INULIN-GROWN FAECALIBACTERIUM PRAUSNITZII CROSS-FEEDS THE HUMAN INTESTINAL EPITHELIUM WITH FRUCTOSE

Gerard Dijkstra  et al.

INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY
INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY

Gerard Dijkstra  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Gerard Dijkstra  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Gerard Dijkstra  et al.

FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Gerard Dijkstra  et al.

DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Gerard Dijkstra  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Gerard Dijkstra  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Gerard Dijkstra  et al.

Item 1 - 20 / 25
1
2